TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35869267
Drug: Oral selinexor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selinexor 60 mg twice weekly (days 1–24) with standard chemotherapy (3 + 7)
Study: 35869267
Drug: Cytarabine 1000
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 1000 mg/m2 twice daily, days 1–6 with selinexor
Study: 35869267
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (3 + 7) without selinexor
Study: 33952438
Drug: Closed incision
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed incision negative pressure wound therapy (NPWT)
Study: 34260849
Drug: Bamlanivimab plus
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab plus Etesevimab (2800 mg each, administered together)
Study: 33587156
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma (CAP) treatment
Study: 32986265
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (6 months of intradialytic exercise)
Study: 34602438
Drug: Femitex‐SP4 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femitex‐SP4 (500 mg powdered herbs in capsule form, twice daily)
Study: 32690739
Drug: Oropharyngeal surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal surfactant (120 mg vial for <26 weeks GA; 240 mg vial for 26-28 +6 weeks GA) in addition to CPAP
Study: 35569763
Drug: Intravitreal 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal 1.0 mg risuteganib
Study: 34062418
Drug: Metformin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 3 × 500 mg (group A)
Study: 34062418
Drug: Metformin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 3 × 1000 mg (group B)
Study: 32022282
Drug: US-approved reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-approved reference biologics
Study: 32022282
Drug: EU-approved reference
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-approved reference biologics
Study: 35124703
Drug: Adjuvant capecitabine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant capecitabine-containing chemotherapy (TX + CEX: capecitabine-docetaxel, followed by cyclophosphamide-epirubicin-capecitabine)
Study: 35124703
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (T + CEF: docetaxel, followed by cyclophosphamide-epirubicin-fluorouracil)
Study: 33813084
Drug: Adrenomedullin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenomedullin (30 μg/kg for 7 days)
Study: 33813084
Drug: Adrenomedullin (56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenomedullin (56 μg/kg for 7 days)
Study: 34422246
Drug: Fast inhalation
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast inhalation and slow exhalation (A) group
Study: 32133329
Drug: Nusinersen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nusinersen treatment
Study: 32027167
Drug: GP40061 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP40061 insulin glargine (GP‐Gla)
Study: 33660798
Drug: Pembrolizumab (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (alone or in combination with chemotherapy)
Study: 33660798
Drug: Pembrolizumab combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab combined with chemotherapy
Study: 33725327
Drug: Standard low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard low-dose protocol stereoradiography
Study: 35122746
Drug: Mindfulness-Based Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Stress Reduction (MBSR) for 6 weeks, 1 hour daily sessions
Study: 35431355
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy
Study: 33998255
Drug: 0/1-hour unmasked
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0/1-hour unmasked hs-cTnT protocol (reported to <5 ng/L)
Study: 33998255
Drug: 0/3-hour masked
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0/3-hour masked hs-cTnT protocol (reported to ≤29 ng/L)
Study: 33998255
Drug: 0/1-hour unmasked
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0/1-hour unmasked hs-cTnT protocol (reported to <5 ng/L) among participants with initial troponin T concentrations ≤29 ng/L
Study: 33998255
Drug: 0/3-hour masked
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0/3-hour masked hs-cTnT protocol (reported to ≤29 ng/L) among participants with initial troponin T concentrations ≤29 ng/L
Study: 33578226
Drug: Enoxaparin 20
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 20 mg twice a day starting 24 h after onset of ICH
Study: 32976660
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam
Study: 34495988
Drug: ChAd63 CAT
Normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd63 CAT vaccine (three-antigen: CSP, AMA1, ME-TRAP)
Study: 34495988
Drug: ChAd63 CA
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd63 CA vaccine (two-antigen: CSP, AMA1)
Study: 35168962
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of desmopressin and VWF-containing concentrate
Study: 35168962
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of desmopressin and VWF-containing concentrate (medical procedures)
Study: 35588887
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg oral twice a day for three days before CPB
Study: 34937388
Drug: Evacetrapib (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib (130 mg); placebo-adjusted percent increase in apoA1 in HDL that contains apoC3: 99%.
Study: 34937388
Drug: Torcetrapib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib (60 mg); placebo-adjusted percent increase in apoA1 in HDL that contains apoC3: 50%.
Study: 34937388
Drug: Both CETP
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CETP inhibitors; increase in apoA1 in HDL that contains apoC1: 71% (evacetrapib) and 40% (torcetrapib).
Study: 34937388
Drug: Both CETP
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CETP inhibitors; no response in HDL that contains apoL1.
Study: 32514702
Drug: Medial midpatellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial midpatellar (MMP) injection of hyaluronic acid (HA)
Study: 32514702
Drug: Anteromedial (AM)
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anteromedial (AM) injection of hyaluronic acid (HA)
Study: 33970454
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy
Study: 32162241
Drug: WP-MND (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: WP-MND (1 or 2 servings daily, 21 g protein, 3 g leucine, 10 µg vitD, 500 mg calcium per serving)
Study: 32162241
Drug: WP-MND (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: WP-MND (1 or 2 servings daily) during OLE
Study: 32833890
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of 1.2 g·d‐1 Beta-Alanine
Study: 34656202
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Couple Therapy (CBCT)
Study: 34656202
Drug: Topical Lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Lidocaine
Study: 35864302
Drug: Betahistine dimesylate
Normalized name: betahistine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine dimesylate 12 mg
Study: 36763929
Drug: Escitalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram treatment
Study: 35986348
Drug: Prisma intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prisma intervention (psychoeducational group intervention) consisting of four weekly group sessions.
Study: 34281376
Drug: Baseline glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline glucose <150 mg/dL
Study: 34281376
Drug: Elevated baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated baseline serum glucose ?150 mg/dL
Study: 37526748
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm
Study: 32306953
Drug: High risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High risk basic (HRB) group - basic prevention regimen including oral-hygiene instruction, hands-on brushing practice, supervised daytime tooth brushing, sealant application, provision of toothbrush, fluoride-containing dentifrice, and a guidebook.
Study: 33386796
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil infusion before balloon dilation or stent placement
Study: 33386796
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil infusion
Study: 32195722
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition supplement containing collagen peptides (10.0 g, once-a-day)
Study: 35354530
Drug: Novel soaking
Normalized name: magnesium sulfate
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Novel soaking solution (dexamethasone, gentamicin, and vitamin B12), soaked for 15 minutes, three times a day for four weeks.
Study: 34789181
Drug: Medication+tDCS (n=15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication+tDCS (n=15, receiving medications plus tDCS with 2 mA intensity over dorsolateral prefrontal cortex for 10 days, two sessions per day each for 20 min)
Study: 34789181
Drug: Medication (n=15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (n=15, receiving mood stabilizers including 2-5 tables of 300 mg lithium, 200 mg sodium valproate, and 200 mg carbamazepine two times per day)
Study: 34789181
Drug: Medication+tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication+tDCS
Study: 35213714
Drug: GLWL‐01 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLWL‐01 (450 mg twice daily)
Study: 34626318
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy
Study: 32320767
Drug: Pivotal trials
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivotal trials for systemic therapies for plaque psoriasis
Study: 34910203
Drug: filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: filgotinib 200 mg plus MTX
Study: 34910203
Drug: filgotinib 100
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: filgotinib 100 mg plus MTX
Study: 35263963
Drug: filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: filgotinib 200 mg
Study: 32487336
Drug: Azithromycin (AZT)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZT) plus Echinacea (5 ml oral suspension, 3 times daily for 10 consecutive days every month for 6 months)
Study: 32487336
Drug: Azithromycin (AZT)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZT) (60 mg/kg divided as 10 mg/kg/day over 6 consecutive days every month for 6 months)
Study: 36244779
Drug: Dexmedetomidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.2 to 0.7 µg/kg/h, DEX group)
Study: 33764851
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g soy protein (∼24–26/day genistein; ∼40–43/day total isoflavones)
Study: 36633795
Drug: Fractional picosecond
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional picosecond 1064 nm Nd: YAG laser (FxPico) treatment
Study: 32464321
Drug: No Aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Aspirin (Control)
Study: 34073918
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNT‐A) injection
Study: 36443490
Drug: α-lactalbumin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lactalbumin (40 g)
Study: 33559440
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with conventional visual stimulation therapy
Study: 33559440
Drug: Conventional visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional visual stimulation therapy
Study: 35393316
Drug: Supervised acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised acute physical exercise therapy prior to immune-chemotherapy infusion
Study: 32827458
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention for intensive BP treatment including protocol‐based treatment using the SPRINT intensive BP management algorithm, dissemination of SPRINT findings, BP audit and feedback, home BP monitoring, and health coaching.
Study: 32827458
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention for intensive BP treatment
Study: 35238969
Drug: Ultra-low-dose (ULD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose (ULD) CT
Study: 35238969
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) CT
Study: 37784098
Drug: Immediate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antibiotic prescription (IAP)
Study: 37784098
Drug: Delayed antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotic prescription (DAP)
Study: 37784098
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prescription (NAP)
Study: 33301246
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (30 μg per dose, two doses, 21 days apart)
Study: 38438427
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine
Study: 35279718
Drug: EV 2
Normalized name: Padcev 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV 2 mg + DNG 2-3 mg
Study: 35279718
Drug: EE 0.03
Normalized name: EE 0.03MG/LEVONORG 0.15MG TAB,28
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 0.03 mg + DNG 2 mg
Study: 35279718
Drug: DNG 2
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNG 2 mg
Study: 32852904
Drug: Mepivacaine (52.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine (52.5 mg)
Study: 32852904
Drug: Hyperbaric Bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Bupivacaine (11.25 mg)
Study: 32852904
Drug: Isobaric Bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric Bupivacaine (12.5 mg)
Study: 33534231
Drug: Biological mesh
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological mesh closure
Study: 35725632
Drug: 24% oral
Normalized name: Entero VU, 24% oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% oral sucrose
Study: 35791269
Drug: Baseline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plus treatment model in a German EMS and health care system
Study: 33858875
Drug: eHealth programme
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth programme comprising balance exercise, cognitive‐motor exercise and cognitive‐behavioural therapy
Study: 35134697
Drug: Pomegranate supplement
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate supplement for 4 weeks
Study: 33950030
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral conjugated equine estrogen (CEE) (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) for women with a uterus (5.7 years)
Study: 33950030
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral CEE (0.625 mg) alone for women with a hysterectomy (7.2 years)
Study: 33836826
Drug: Ivermectin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (300 mcg/kg) administered daily for three consecutive days
Study: 33836826
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered daily for three consecutive days
Study: 32176305
Drug: Smoking cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cigarettes monthly or less
Study: 32176305
Drug: Smoking cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cigarettes daily
Study: 35416163
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (anterior‐superior RCT type 1,2,3 or combination)
Study: 35416163
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (posterior‐superior RCT type 3, 4, 5 or combination)
Study: 35791906
Drug: Daily co-use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily co-use of alcohol and cannabis
Study: 34668237
Drug: Hair lotion
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hair lotion containing creatine, acetyl tetrapeptide‐2 and B vitamins with mild shampoo
Study: 32672584
Drug: Topical travoprost
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical travoprost (once-daily)
Study: 32883333
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) 0.5 mg/kg twice a day for 7 days, then 0.5 mg/kg once a day for 3 days
Study: 34790015
Drug: nucleos(t)ide analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: nucleos(t)ide analog (NUC)-based therapy
Study: 36496154
Drug: Tailored physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored physical therapy program (Enhanced PT)
Study: 36496154
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for chronic pain (if re-randomized)
Study: 36496154
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation therapy (if re-randomized)
Study: 33558351
Drug: SISU software
Approvals — FDA: no, EMA: no, PMDA: no
Description: SISU software agent-based intervention, delivered over 3 consecutive days, based on therapeutic writing and acceptance and commitment therapy principles.
Study: 33558351
Drug: SISU software
Approvals — FDA: no, EMA: no, PMDA: no
Description: SISU software agent-based intervention
Study: 35734648
Drug: Pre-operative antibiotics
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative antibiotics (intravenous cefazolin 2-g)
Study: 32468765
Drug: No pre-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No pre-operative antibiotics
Study: 33045448
Drug: Transvaginal ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal ovarian needle puncture prior to induction with aromatase inhibitors and gonadotropins
Study: 33045448
Drug: Induction using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction using aromatase inhibitors (Letrozol 2.5 mg twice daily for 5 days) and FSH (75 IU daily from cycle day 3)
Study: 33736523
Drug: Statin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin prescription in HIV-negative patients
Study: 33736523
Drug: Statin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin prescription in HIV-positive patients
Study: 33736523
Drug: Aspirin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin prescription in HIV-negative patients
Study: 33736523
Drug: Aspirin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin prescription in HIV-positive patients
Study: 34209080
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training (PFMT) - supervised exercise twice a week for 12 weeks
Study: 32686119
Drug: Hand‐Arm Bimanual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand‐Arm Bimanual Intensive Therapy (HABIT) (90 hours)
Study: 34908536
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (20 mg/kg)
Study: 34908536
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (up to a serum level of 0.8‐1.5 mEq/L)
Study: 32381151
Drug: VC injection
Normalized name: phenylephrine hydrochloride / promethazine hydrochloride Oral Solution [Phenergan VC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC injection pre-transit (5 g sodium ascorbate/steer)
Study: 32381151
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection pre-transit and VC injection post-transit
Study: 32381151
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection pre- and post-transit (CON)
Study: 34437978
Drug: Mast-cell inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mast-cell inhibitors